Free Trial

Spero Therapeutics (SPRO) Competitors

Spero Therapeutics logo
$2.90 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.91 +0.01 (+0.38%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SPRO vs. NUVB, IOVA, ABUS, DAWN, GHRS, SION, STOK, CDXC, XNCR, and KALV

Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Nuvation Bio (NUVB), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Sionna Therapeutics (SION), Stoke Therapeutics (STOK), ChromaDex (CDXC), Xencor (XNCR), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.

Spero Therapeutics vs. Its Competitors

Nuvation Bio (NYSE:NUVB) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

In the previous week, Nuvation Bio had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 4 mentions for Nuvation Bio and 3 mentions for Spero Therapeutics. Nuvation Bio's average media sentiment score of 0.65 beat Spero Therapeutics' score of 0.47 indicating that Nuvation Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvation Bio
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Spero Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Nuvation Bio has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Spero Therapeutics has higher revenue and earnings than Nuvation Bio. Spero Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation Bio$7.87M88.85-$567.94M-$2.35-0.87
Spero Therapeutics$47.98M3.38-$68.57M-$1.28-2.27

Spero Therapeutics has a net margin of -156.48% compared to Nuvation Bio's net margin of -5,534.21%. Nuvation Bio's return on equity of -44.14% beat Spero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvation Bio-5,534.21% -44.14% -32.97%
Spero Therapeutics -156.48%-123.50%-58.96%

Nuvation Bio currently has a consensus price target of $7.17, indicating a potential upside of 248.74%. Spero Therapeutics has a consensus price target of $5.00, indicating a potential upside of 72.41%. Given Nuvation Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Nuvation Bio is more favorable than Spero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvation Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Spero Therapeutics
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 29.9% of Nuvation Bio shares are held by company insiders. Comparatively, 5.5% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Nuvation Bio beats Spero Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Spero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRO vs. The Competition

MetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$162.14M$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio-2.2721.3126.1719.90
Price / Sales3.38278.47414.67113.66
Price / CashN/A41.4736.1356.90
Price / Book3.417.518.055.38
Net Income-$68.57M-$55.05M$3.15B$248.50M
7 Day PerformanceN/A2.45%1.85%2.97%
1 Month Performance5.84%7.33%4.81%6.02%
1 Year Performance122.22%5.38%34.86%20.39%

Spero Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRO
Spero Therapeutics
4.2914 of 5 stars
$2.90
flat
$5.00
+72.4%
+126.6%$162.14M$47.98M-2.27150
NUVB
Nuvation Bio
3.4764 of 5 stars
$2.02
+2.3%
$7.17
+255.7%
-38.7%$670.32M$7.87M-0.8660High Trading Volume
IOVA
Iovance Biotherapeutics
4.7042 of 5 stars
$1.85
-6.6%
$12.22
+560.7%
-78.4%$661.19M$164.07M-1.49500
ABUS
Arbutus Biopharma
1.9235 of 5 stars
$3.41
-0.6%
$5.50
+61.3%
+1.9%$656.94M$6.17M-8.3290
DAWN
Day One Biopharmaceuticals
2.1421 of 5 stars
$6.48
+2.5%
$30.57
+371.8%
-51.3%$640.61M$131.16M-9.1360Upcoming Earnings
GHRS
GH Research
1.9222 of 5 stars
$11.68
-5.1%
$32.00
+174.0%
+8.3%$640.47MN/A-14.7810News Coverage
SION
Sionna Therapeutics
N/A$14.10
-2.7%
$38.50
+173.0%
N/A$639.36MN/A0.0035News Coverage
Positive News
Insider Trade
Gap Up
STOK
Stoke Therapeutics
4.0242 of 5 stars
$11.59
+0.1%
$23.20
+100.2%
-16.0%$632.23M$36.56M14.67100Analyst Forecast
CDXC
ChromaDex
3.1841 of 5 stars
N/A$9.03
+∞
N/A$611.50M$99.60M787.29120
XNCR
Xencor
4.0421 of 5 stars
$8.41
-1.5%
$28.00
+232.9%
-57.6%$607.80M$110.49M-2.75280
KALV
KalVista Pharmaceuticals
4.2788 of 5 stars
$11.93
-1.8%
$24.83
+108.2%
-2.5%$604.04MN/A-3.21100

Related Companies and Tools


This page (NASDAQ:SPRO) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners